Chandigarh, January 24, 2024: Venus Remedies, a globally recognised pharmaceutical company, has been awarded the Good Manufacturing Practices (GMP) certification for its facilities from the Ministry of Health, Libya. This accomplishment is a testament to the company's commitment to quality, safety and efficiency in the production of injectable pharmaceuticals, including oncology, antibiotic and anticoagulant medications.

Mr. Saransh Chaudhary, CEO of Venus Medicine Research Centre, said, " The GMP certification from Libya adds to Venus Remedies' portfolio of international approvals from 25 regulators, complementing our existing certifications in Africa from Morocco, South Africa, Tanzania, Kenya, Uganda, Sudan and other African countries.  This GMP certification reflects our collaborative efforts in the African pharmaceutical industry, a key focus area of our global expansion strategy.”

This recognition demonstrates Venus Remedies’ persistence in adhering to stringent manufacturing standards across its global operations and is in line with the company’s commitment to enhancing healthcare solutions that benefit people the world over.

Libya’s pharmaceutical imports, valued at US $514 million in 2021, have grown at a rate of 2.81% over the previous year. Its strategic location in Africa and evolving pharmaceutical landscape provide Venus Remedies with an opportunity to contribute positively to the region's healthcare sector.  The $46.8 billion pharmaceutical market of Africa, as in 2022, is expected to grow at a CAGR of 8.3% to reach $110.9 billion by 2023. This certification is a step towards enhancing the company's presence in Africa, aligning with its broader vision of improving access to life-saving medicines across the continent.

Lauding the achievement, Mr. Akshansh Chaudhary, Executive Director of Venus Remedies, said, "We are thankful to our customers, partners and stakeholders for their constant support. Their trust in our company drives our pursuit of excellence."

Venus Remedies continues to contribute to global healthcare, aiming to improve public health standards in Libya and other regions in line with its mission of advancing healthcare solutions worldwide.

About Venus Remedies

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European- GMP, WHO-GMP and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 125 registered trademarks and 25 copyrights for its innovative research products.